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Mesenchymal stem cell (MSC) based therapies are currently being evaluated as a putative therapeutic in
numerous human clinical trials. Recent reports have established that exosomes mediate much of the
therapeutic properties of MSCs. Exosomes are nanovesicles which mediate intercellular communication,
transmitting signals between cells which regulate a diverse range of biological processes. MSC-derived
exosomes are packaged with numerous types of proteins and RNAs, however, their metabolomic and
lipidomic proﬁles to date have not been well characterized. We previously reported that MSCs, in
response to priming culture conditions that mimic the in vivo microenvironmental niche, substantially
modulate cellular signaling and signiﬁcantly increase the secretion of exosomes. Here we report that
MSCs exposed to such priming conditions undergo glycolytic reprogramming, which homogenizes MSCs’
metabolomic proﬁle. In addition, we establish that exosomes derive from primed MSCs are packaged
with numerous metabolites that have been directly associated with immunomodulation, including M2
macrophage polarization and regulatory T lymphocyte induction.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In recent years, the therapeutic potential and safety of mesen-
chymal stem/stromal cells (MSCs) has been investigated preclini-
cally and clinically, in the context of immune regulation and
regeneration in a variety of diseases [1e3]. The therapeutic effects
of MSCs on tissue repair and regeneration are mediated by their
paracrine activity via various secreted factors, including exosomes
[4e11]. Exosomes are nano-sized vesicles that comprise a robust
inter-cellular communication system [12,13]. There are now overDavis Medical Center, 2921
A.
erson).
r Inc. This is an open access article200 published reports indicating that exosomes are a critical active
pharmaceutical ingredient that is responsible for mediating much
of the therapeutic effects of MSCs, including their immunomodu-
latory properties [14e17]. The application of exosomes isolated and
puriﬁed from MSC conditioned media holds several potential ad-
vantages of the use of cell-based therapies, including increased
potency, greater consistency and lower cost. Previously we have
reported that exosomes derived from primed MSC possess potent
tissue healing properties, and producing a much higher yield of
exosomal material, which has important implications for the
translation of this technology [5]. Exosomes transport a variety of
factors including proteins and RNAs [18]. To date, most studies have
focused on the RNA, and to a lesser extent, the protein packaged
into exosomes derived from MSCs [19e21]. Consequently, the
metabolomic proﬁle of MSC-derived exosomes, remains largelyunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Metabolomics uses mass spectrometry to identify and quantify a
variety of small molecules that are indicative of the metabolic, and
physiological status of cellular subpopulations [22]. This analytical
approach affords the analysis of a large number of samples and
characterizes the molecular response of a biological system to any
perturbation in its microenvironment [23]. Metabolomics enables
the detection of differential abundance of metabolites between two
conditions and adds value to translational studies focusing on
elucidating the underlying the dynamicmolecular processes within
a given system [24]. We have previously established that pMEX are
packaged with biologically active, regenerative proteins [4]. How-
ever, there are few metabolic or lipidomic studies of exosomes
reported to date.
Here we report that exosomes derived from primed MSCs are
packaged with a variety of metabolites and lipid membrane com-
ponents. We compare the metabolomic and lipidomic proﬁles of
classically cultured MSC vs primed MSCs demonstrating their
metabolic reprogramming under such microenvironmental condi-
tions. We establish that exosomes derived from primed MSCs
(pMEX) are packaged with distinct proﬁle of metabolites, the ma-
jority of which have been associated with immunomodulation.
These ﬁndings suggest that further studies establishing the
metabolite payload of MSC-derived exosomes may yield insights
into their underlying physiological and cell signaling properties.
2. Materials and methods
2.1. Sample preparation for GC-TOF MS and LC-QTOF MS/MS
analysis
Flash frozen cell pellets were ground using a GenoGrinder 2010
(SPEX SamplePrep) for 2min at 1350 rpm. Cell pellets were then
extracted with 225 mL of methanol at 20 C containing an internal
standard mixture described previously [25], and 750 mL of MTBE
(methyl tertiary butyl ether) (Sigma Aldrich) at 20 C containing
cholesteryl ester 22:1. Samples were shaken for 6min at 4 C with
an Orbital Mixing Chilling/Heating Plate (Torrey Pines Scientiﬁc
Instruments, Calsbad, CA). Then 188 mL of LC-MS grade water
(Fisher) was added. Samples were vortexed, centrifuged and the
upper (non-polar) and bottom (polar) layers were collected (350 mL
and 125 mL, respectively) and evaporated to dryness.
The non-polar layer was re-suspended in a methanol:toluene
(9:1, v/v) mixture containing 50 ng/ml CUDA ((12-
[[(cyclohexylamino)carbonyl]amino]-dodecanoic acid) (Cayman
Chemical, Ann Arbor, MI) vortexed, sonicated for 5min and
centrifuged and prepared for lipidomic analysis. Half the polar layer
was resuspended in an acetonitrile:water (4:1, v/v) mixture with
5 mg/ml Val-Try-Val (Sigma) sonicated for 5min and centrifuged
and prepared for HILIC-QTOF MS/MS analysis. The second polar
phase aliquots were derivatized with 10 mL of methoxyamine hy-
drochloride in pyridine (40mg/mL) by shaking at 30 C for 90min
followed by trimethylsilylation with 90 mL of N-methyl-N-(trime-
thylsilyl) triﬂuoroacetamide (MSTFA, Sigma-Aldrich) by shaking at
37 C for 30min containing C8eC30 fatty acid methyl esters
(FAMEs) as internal standards. Derivatized samples were subse-
quently submitted for analysis by GC-TOF MS (0.5 mL injection).
Method blanks and pooled human plasma (BioIVT) were included
as quality control samples for all platforms and prepared in same
manner.
2.2. Chromatographic and mass spectrometric conditions for
lipidomic LC-QTOF MS analysis.
For analysis of the non-polar phase, re-suspended samples wereinjected at 1 mL ESI (þ) and 5 mL for ESI(), onto a Waters Acquity
UPLC CSH C18 (100 mm length x 2.1 mm id; 1.7 mm particle size)
with a Waters Acquity VanGuard CSH C18 pre-column
(5 mm  2.1 mm id; 1.7 mm particle size) at 65 C coupled to an
Agilent 1290 Inﬁnity UHPLC (Agilent Technologies, Santa Clara, CA).
For positive mode 10 mM ammonium formate and 0.1% formic acid
were used and 10 mM ammonium acetate (SigmaeAldrich) was
used for negative mode. Both positive and negative modes used the
same mobile phase composition of (A) 60:40 v/v acetonitrile:water
(LC-MS grade) and (B) 90:10 v/v isopropanol:acetonitrile. The
gradient started at 0 min with 15% (B), 0e2 min 30% (B), 2e2.5 min
48% (B), 2.5e11 min 82% (B), 11e11.5 min 99% (B), 11.5e12 min 99%
(B), 12e12.1 min 15% (B), and 12.1e15 min 15% (B). A ﬂow rate of
0.6 mL/min was used. For data acquisition an Agilent 6550 QTOF
with a jet stream electrospray source with the following parame-
ters was used: mass range, m/z 50e1700; capillary voltage, ±3 kV;
nozzle voltage, ±1 kV; gas temperature, 200 C; drying gas (nitro-
gen), 14 L/min; nebulizer gas (nitrogen), 35 psi; sheath gas tem-
perature, 350 C; sheath gas ﬂow (nitrogen), 11 L/min; acquisition
rate, 2 spectra/s. For lipid identiﬁcation, MS/MS spectra were
collected at a collision energy of 20 eV with an acquisition rate MS1
of 10 spectra/s (100ms) and an acquisition rate for MS/MS of 13
spectra/s (77ms) with 4 precursor ions per cycle… Mass accuracy
was maintained by constant reference ion infusion (purine and HP-
0921 in an acetonitrile:water mixture).
2.3. Chromatographic and mass spectrometric conditions for polar
metabolite HILIC-QTOF MS analysis
Five microliters of re-suspended sample was injected onto a
Waters Acquity UPLC BEH Amide column (150 mm length x 2.1 mm
id; 1.7 mmparticle size)with an additionalWaters Acquity VanGuard
BEH Amide pre-column (5 mm  2.1 mm id; 1.7 mm particle size)
maintained at 45 C coupled to an Agilent 1290 Inﬁnity UHPLC. The
mobile phases were prepared with 10 mM ammonium formate and
0.125% formic acid (SigmaeAldrich) in either 100% LC-MS grade
water for mobile phase (A) or 95:5 v/v acetonitrile:water for mobile
phase (B). Gradient elutionwas performed from100% (B) at 0e2min
to 70% (B) at 7.7 min, 40% (B) at 9.5 min, 30% (B) at 10.25 min, 100%
(B) at 12.75 min, isocratic until 16.75 min with a column ﬂow of
0.4 mL/min. Spectra were collected using a 5600 þ TripleTOF MS
(SCIEX, Framingham, MA, USA) using data dependent mode for MS/
MS spectra acquisition. Data was collected in ESI(þ) mode with the
following parameters: m/z 50e1700, curtain gas: 35, ion source gas
1 and 2: 60, temperature: 350 C, ion spray voltage ﬂoating:þ4.5 kV,
declustering potential: 80 V, MS1 accumulation time 100 ms, MS2
accumulation time 50 ms, dependent product ion scan number 8,
intensity threshold 1000, active precursor exclusion after 2 spectra
for 5 s, collision energy 20 eV with 15 eV collision energy spread.
Mass accuracy was maintained through calibration every 10 in-
jections using APCI positive calibration solution delivered using a
calibration delivery system.
2.4. LC-MS/MS data processing using MS-DIAL and statistics
Both lipidomic and HILIC data processing was performed using
MS-DIAL2613 for deconvolution, peak picking, alignment, and
identiﬁcation. For both data sets, in house m/z and retention time
libraries were used in addition to MS/MS spectra databases in msp
format as previously described [27]. Features were reported when
present in at least 50% of samples in each group. Statistical analysis
was done by ﬁrst normalizing data using the sum of the knowns, or
mTIC normalization, to scale each sample. Peak heights were then
submitted using R to DeviumWeb and normalized further by log
transformation and Pareto scaling. ANOVA analysis was performed
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2.5. Chromatographic and mass spectrometric conditions for GC-
TOF MS analysis
Primary metabolite data was collected using a Leco Pegasus IV
time-of-ﬂight (TOF) MS (Leco Corporation, St. Joseph, MI) coupled
to an Agilent 6890 GC (Agilent Technologies, Santa Clara) equipped
with a 30m long 0.25mm id Rtx-5 Sil MS column (0.25 mm ﬁlm
thickness) and a Gerstel MPS2 automatic liner exchange system
(Gerstel GMBH & Co. KG, Ruhr, Germany). The chromatographic
gradient used a constant ﬂow of 1ml/min with following gradient:
50 C (1min), 20 C/min to 330 C, hold 5min. Mass spectrometry
data was collected using 1525 V detector voltage at m/z 85e500
with 17 spectra/s, electron ionization at 70 eV and an ion source
temperature of 250 C. QC injections, blanks and pooled human
plasma were used for quality assurance throughout the run. Data
was processed by ChromaTOF for deconvolution, peak picking, and
BinBase283 for metabolite identiﬁcations.
3. Results
3.1. Primed MSCs undergo metabolic lipidomic reprogramming
MSCs are typically cultured and expanded in high serumFig. 1. Metabolomic and lipidomic proﬁling of primed MSCs demonstrated signiﬁcant met
lipid membrane components (A, B). Similarity analysis using Pearson's correlation determ
biological replicates, as compared to classically cultured MSCs (C). N¼ 6 per condition, sig
discovery rate of 1%. Similarity matrix was calculated using the Pearson correlation functiocontaining media and with atmospheric oxygen tension (~21%)
[29]. Upon administration, MSCs experience a remarkable shift in
the microenvironmental niche, including much lower exposure to
growth factors, as well as substantially lower oxygen tension (eg
1e5% O2) [30]. Most published reports to date have focused on
elucidating MSC physiology while under classic expansion culture
conditions [31]. Upon serum deprivation and hypoxia, MSC un-
dergometabolic reprogramming [32]. We sought to determine how
the metabolic reprogramming of MSCs exposed to serum depriva-
tion and hypoxia inﬂuenced their metabolomic and lipidomic
proﬁles. MSCs were isolated from human bone aspirates using ca-
nonical methods, as previously described [5]. The resulting cells
were veriﬁed to express established MSC surface markers via ﬂow
cytometry, as previously reported [4]. At passage 5, expansion
media was removed, and cells were washed 3 times with 1X PBS.
MSCs either received expansion and were cultured at atmospheric
oxygen tensions (~21%), or priming conditions consisting of serum
deprivation and culturing under hypoxic conditions, 1% O2.
Following 48 h of incubation, cells were processed for metabolomic
and lipidomic proﬁling using mass spectrometry.
PrimedMSCs (pMSC) exposed to hypoxia and serum deprivation
resulted in the increased expression of dipeptides, suggesting that
hypoxic MSCs increase their pool of free amino acids to fulﬁll the
energetic demands that cannot be sufﬁciently provided from the
glycolytic ﬂux (Fig. 1A). Ingenuity Pathway Analysis (IPA) ofabolic reprogramming, increased dipeptide expression, and substantial modulation of
ined that priming conditions greatly increased the metabolic homogeneity of MSC
niﬁcance calculated with T-tests with a multi-testing correction analysis using a false
n of the Broad Institute's Morpheus tool.
Fig. 2. Mass spectrometry metabolic analysis determined that MSCs exposed to hypoxia and serum deprivation signiﬁcantly modulated amino acid, nucleoside, and carbohydrate
metabolism based on chemical ontology analysis using the ChemRICH tool developed by Barupal et al. (A). Analysis of metabolites associated with carbohydrate metabolism
determined that primed MSCs downregulate several pathways related to aerobic respiration. N¼ 6 per condition. For ChemRICH analysis enrichment p-values are given by the
KolmogoroveSmirnov-test. For Kreb's cycle analysis signiﬁcance calculated with T-tests with a multi-testing correction analysis using a false discovery rate of 1%.
Fig. 3. Exosomes derived from MSCs exposed to serum deprivation and hypoxia are packaged with clustered networks of metabolites associated with amino acid, nucleoside, and
carbohydrate metabolic pathways. Pathways associations determined using KEGG Metabolic Mapper function using high conﬁdence metabolites with peak intensities signiﬁcantly
above background, n¼ 6.
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prosurvival metabolic proﬁle (Fig. S1). Lipidomics proﬁling deter-
mined that pMSC decreased expression of numerous lipid mem-
brane components, consistent with previous reports of their
differential morphology (Fig. 1B). Biological replicates of pMSC
were also metabolically more similar to each other and displayed
signiﬁcantly less batch to batch variation thanMSCs cultured under
expansion conditions (Fig. 1C). Metabolic examination using the
ChemRICH analysis, which creates chemical clusters based onFig. 4. Mass spectrometry based lipidomic analysis established exosomes derived from prim
lysophosphatidylcholines, and phosphatidylethanolamine phospholipids, as compared to pM
established to possess immunoregulatory properties (D), using metabolites identiﬁed withstructural similarity [33], demonstrated that pMSC modulated
expression of numerous nucleosides, biosynthetic and glycolytic
associated metabolites, indicating their metabolic reprogramming
(Fig. 2A). Signiﬁcant alterations in glycolysis and TCA cycle in-
termediates in pMSC as compared to MSC, suggest a conversion
from aerobic respiration to glycolytic metabolism (Fig. 2B). Further
IPA analysis established that pMSC metabolites reﬂected a low
carbohydrate environment (Fig. S2). Collectively, these data
demonstrate that MSCs undergo substantial metaboliced MSCs are packaged with higher fractions of lipid membrane components, ceramide,
SCs (AeC). pMEX are packaged with numerous metabolites, including 21 metabolites
high conﬁdence above background, n¼ 6.
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sion culture conditions, to conditions that mimic the microenvi-
ronmental they experience upon administration.
3.2. Exosomes derived from primed MSCs are packaged with
metabolites associated with immunomodulation
Over 200 studies have now been published establishing the
therapeutic properties of MEX in numerous animal models of dis-
ease [34e36]. Several reports have also established the immuno-
modulatory properties of MEX [37e39]. Here we demonstrate that
exosomes derived from pMSC (pMEX) are packaged with numerous
primary metabolites, clustered in metabolic networks associated
with amino acids, carbohydrates and nucleosides biosynthetic
pathways. (Fig. 3). Comparison of the metabolomic proﬁle with our
previous proteomics data determined that pMEX are packaged with
numerous proteins that correspond to the enzymatic and signaling
pathways associated with several of the metabolites detected in
pMEX (Fig. S3). Using lipidomic analysis we established that pMEX
ceramide, lysophosphatidylcholines, and phosphatidylethanol-
amine phospholipids, are present at substantially higher ratios as
compared to their parental cells of origin (pMSC) (Fig. 4A and B).
Many of these factors are associated with lipid rafts and ceramide
platforms that have been established to be central communication
hubs of receptor mediated inter-cellular signaling. In addition,
pMEX are packaged with 21 distinct metabolites that have been
directly associated with immunoregulation, including: adenosine,
arginine, aspartic acid, cholesterol, glutamine, nicotinamide, UDP-N-
acetylglucosamine, 50-deoxy-50-methylthioadenosine, palmitic acid
and isoleucine. Collectively, these metabolites have been directly
associated with themodulation of anti-inﬂammatory responses, M2
macrophage polarization and induction of regulatory T lymphocytes
(Fig. 4C) [40e53]. These data establish that pMEX are packagedwith
numerous metabolites that have been associated with anti-
inﬂammatory and immunoregulatory functions.
4. Discussion
MSCs and their derived exosomes possess therapeutic potential,
but little is currently known about their associated metabolic and
lipid membrane proﬁles [54]. Historically, metabolites and cellular
lipids have been viewed as relatively inert by-products of various
cellular activities [55e57]. However, a growing body of evidence
indicates that many metabolites possess functional properties
capable of inﬂuencing cellular physiology, and immunological
properties [58e61] which we deﬁne as epimetabolites [61]. Here,
we report that priming conditions greatly decreases the variability
of MSC batches, on a metabolic level. We also demonstrate for the
ﬁrst time that pMEX are package with numerous metabolites that
may underly some of their immunomodulatory properties.
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